These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 10351160)

  • 1. Logistical problems of supplying leucodepleted blood components within the national blood service.
    Tandy N
    Transfus Sci; 1998 Dec; 19(4):373-4. PubMed ID: 10351160
    [No Abstract]   [Full Text] [Related]  

  • 2. Operational and research approaches to universal leucodepletion in Scotland.
    Prowse C
    Transfus Sci; 1998 Dec; 19(4):367-9. PubMed ID: 10351158
    [No Abstract]   [Full Text] [Related]  

  • 3. Universal leucodepletion--practical and regulatory consequences.
    Barrowcliffe TW
    Transfus Sci; 1998 Dec; 19(4):361. PubMed ID: 10351156
    [No Abstract]   [Full Text] [Related]  

  • 4. International views on universal leucodepletion: the perspective in NBS, England.
    Wallington T
    Transfus Sci; 1998 Dec; 19(4):347-8. PubMed ID: 10351150
    [No Abstract]   [Full Text] [Related]  

  • 5. Validation approaches selective/universal leucodepletion: the need for standardised validation strategies.
    Seghatchian MJ; Krailadsiri P
    Transfus Sci; 1998 Dec; 19(4):363-5. PubMed ID: 10351157
    [No Abstract]   [Full Text] [Related]  

  • 6. International views on universal leucodepletion: the perspective in Germany.
    Seitz MD
    Transfus Sci; 1998 Dec; 19(4):359-60. PubMed ID: 10351155
    [No Abstract]   [Full Text] [Related]  

  • 7. International views on universal leucodepletion: the perspective in Portugal.
    de Sousa G
    Transfus Sci; 1998 Dec; 19(4):351-2. PubMed ID: 10351152
    [No Abstract]   [Full Text] [Related]  

  • 8. Perspective on Nordic views on selective/universal leukodepletion.
    Flesland O
    Transfus Sci; 1998 Dec; 19(4):355-7. PubMed ID: 10351154
    [No Abstract]   [Full Text] [Related]  

  • 9. International views on universal leucodepletion: the perspective in NBS, Ireland.
    Murphy W
    Transfus Sci; 1998 Dec; 19(4):349-50. PubMed ID: 10351151
    [No Abstract]   [Full Text] [Related]  

  • 10. NBS approaches to the approval of suppliers of leucodepletion systems.
    Smith KJ
    Transfus Sci; 1998 Dec; 19(4):371-2. PubMed ID: 10351159
    [No Abstract]   [Full Text] [Related]  

  • 11. Challenges in QA of leucodepleted blood component and current standard(s). Challenges in quality assurance of leukoreduced components.
    Dumont LJ
    Transfus Sci; 1998 Dec; 19(4):377-80. PubMed ID: 10351162
    [No Abstract]   [Full Text] [Related]  

  • 12. NBA/NBS perspective on nvCJD.
    Wallington T
    Transfus Sci; 1998 Dec; 19(4):329-30. PubMed ID: 10351146
    [No Abstract]   [Full Text] [Related]  

  • 13. The risk of transmission of nvCJD by blood transfusion and the potential benefits of leucodepletion.
    Turner M
    Transfus Sci; 1998 Dec; 19(4):331-2. PubMed ID: 10351147
    [No Abstract]   [Full Text] [Related]  

  • 14. Potential clinical benefits and cost savings of universal leucocyte-depletion of blood components.
    Murphy MF
    Transfus Sci; 1998 Dec; 19(4):343-6. PubMed ID: 10351149
    [No Abstract]   [Full Text] [Related]  

  • 15. Leukodepleted blood components: definition of a standard.
    Andreu G; Masse M; Royer SD; Tardivel R
    Transfus Sci; 1998 Dec; 19(4):381-3. PubMed ID: 10351163
    [No Abstract]   [Full Text] [Related]  

  • 16. French evaluation of conditions for the systematic implementation of leucocyte removal in labile blood products (LBP).
    Chamfly V
    Transfus Sci; 1998 Dec; 19(4):333-42. PubMed ID: 10351148
    [No Abstract]   [Full Text] [Related]  

  • 17. International views on universal leucodepletion: the perspective in The Netherlands.
    de Wit HC
    Transfus Sci; 1998 Dec; 19(4):353-4. PubMed ID: 10351153
    [No Abstract]   [Full Text] [Related]  

  • 18. Developing effective working partnership with manufacturers.
    Pujol-Reyz A
    Transfus Sci; 1998 Dec; 19(4):375-6. PubMed ID: 10351161
    [No Abstract]   [Full Text] [Related]  

  • 19. Leukocyte reduction of blood components: public policy and new technology.
    Dzik S; Aubuchon J; Jeffries L; Kleinman S; Manno C; Murphy MF; Popovsky MA; Sayers M; Silberstein LE; Slichter SJ; Vamvakas EC
    Transfus Med Rev; 2000 Jan; 14(1):34-52. PubMed ID: 10669939
    [No Abstract]   [Full Text] [Related]  

  • 20. Balancing evidence and public opinion in health technology assessments: the case of leukoreduction.
    Cleemput I; Leys M; Ramaekers D; Bonneux L
    Int J Technol Assess Health Care; 2006; 22(4):403-7. PubMed ID: 16984672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.